Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Simulations Plus, Inc. (SLP) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Simulations Plus, Inc. (SLP) - free report >>
Image: Bigstock
Company News for July 12, 2017
• Shares of Amicus Therapeutics, Inc. (FOLD - Free Report) soared 25.9% following news that the company has received permission from the U.S. Food and Drug Administration to submit an experimental drug for approval
• Simulations Plus, Inc.’s (SLP - Free Report) shares gained 6.2% after posting fiscal third-quarter revenues of $6.75 million, outpacing the Zacks Consensus Estimate of $6 million
• Shares of Arena Pharmaceuticals, Inc. surged 41.4% following positive mid-stage trial results for its drug ralinepag
• Evogene Ltd’s (EVGN - Free Report) shares surged 10.8% after the company declared that it has reached an important stage in crop disease collaboration with Monsanto Company